Related Experiment Video
Updated: Sep 24, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
CD103+ T Cells May Be a Useful Biomarker in Borrmann Type 4 Gastric Cancer
Takuya Mori1, Hiroaki Tanaka1, Sota Deguchi1
1Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Background/Aim:
Recently, several studies have reported that CD103 T cells are associated with antitumor immunity in gastric cancer (GC). However, the significance of CD103 T cells in Borrmann type 4 GC remains unclear. The aim of this study is to assess the association of CD103 T cells with type 4 GC.
Materials And Methods:
Tissue samples obtained from surgically resected specimens of patients with type 4 GC were collected, and immunohistochemical staining was performed to detect the presence of CD103 T cells.
Results:
A total of 46 patients were analyzed. In some patients, high CD103 expression was observed, and patients with high CD103 expression tended to have a better prognosis than those with low CD103 expression. In particular, for patients who receive doublet chemotherapy after surgery, high CD103 expression was associated with a good prognosis.
Conclusion:
CD103 T cells may be a prognostic marker in type 4 GC.
